tetano
Editor, Senior Moderator
J Transl Med
. 2024 Aug 12;22(1):755.
doi: 10.1186/s12967-024-05556-2. Immune signature in vaccinated versus non-vaccinated aged people with COVID-19 pneumonia
Ruggiero Alessandra[SUP] #[/SUP][SUP] 1 [/SUP], Caldrer Sara[SUP] #[/SUP][SUP] 2 [/SUP], Pastori Claudia[SUP] 3 [/SUP], Gianesini Natasha[SUP] 1 [/SUP], Cugnata Federica[SUP] 4 [/SUP], Brombin Chiara[SUP] 4 [/SUP], Fantoni Tobia[SUP] 1 [/SUP], Tais Stefano[SUP] 2 [/SUP], Rizzi Eleonora[SUP] 2 [/SUP], Matucci Andrea[SUP] 2 [/SUP], Mayora-Neto Martin[SUP] 5 [/SUP], Uberti-Foppa Caterina[SUP] 6 [/SUP], Temperton Nigel[SUP] 5 [/SUP], Di Serio Mariaclelia Stefania[SUP] 4 [/SUP], Lopalco Lucia[SUP] #[/SUP][SUP] 7 [/SUP], Piubelli Chiara[SUP] #[/SUP][SUP] 2 [/SUP]
Affiliations
Background: A definition of the immunological features of COVID-19 pneumonia is needed to support clinical management of aged patients. In this study, we characterized the humoral and cellular immune responses in presence or absence of SARS-CoV-2 vaccination, in aged patients admitted to the IRCCS San Raffaele Hospital (Italy) for COVID-19 pneumonia between November 2021 and March 2022.
Methods: The study was approved by local authorities. Disease severity was evaluated according to WHO guidelines. We tested: (A) anti-SARS-CoV-2 humoral response (anti-RBD-S IgG, anti-S IgM, anti-N IgG, neutralizing activity against Delta, BA1, BA4/5 variants); (B) Lymphocyte B, CD4 and CD8 T-cell phenotype; (C) plasma cytokines. The impact of vaccine administration and different variants on the immunological responses was evaluated using standard linear regression models and Tobit models for censored outcomes adjusted for age, vaccine doses and gender.
Result: We studied 47 aged patients (median age 78.41), 22 (47%) female, 33 (70%) older than 70 years (elderly). At hospital admission, 36% were unvaccinated (VAC[SUB]no[/SUB]), whilst 63% had received 2 (VAC[SUB]2[/SUB]) or 3 doses (VAC[SUB]3[/SUB]) of vaccine. During hospitalization, WHO score > 5 was higher in unvaccinated (14% in VAC[SUB]3[/SUB] vs. 43% in VAC[SUB]2[/SUB] and 44% VACno). Independently from vaccination doses and gender, elderly had overall reduced anti-SARS-CoV-2 humoral response (IgG-RBD-S, p = 0.0075). By linear regression, the anti-RBD-S (p = 0.0060), B (p = 0.0079), CD8 (p = 0.0043) and Th2 cell counts (p = 0.0131) were higher in VAC[SUB]2 + 3[/SUB] compared to VAC[SUB]no[/SUB]. Delta variant was the most representative in VAC[SUB]2[/SUB] (n = 13/18, 72%), detected in 41% of VAC[SUB]no[/SUB], whereas undetected in VAC[SUB]3,[/SUB] and anti-RBD-S production was higher in VAC[SUB]2[/SUB] vs. VAC[SUB]no[/SUB] (p = 0.0001), alongside neutralization against Delta (p = 0141), BA1 (p = 0.0255), BA4/5 (p = 0.0162). Infections with Delta also drove an increase of pro-inflammatory cytokines (IFN-α, p = 0.0463; IL-6, p = 0.0010).
Conclusions: Administration of 3 vaccination doses reduces the severe symptomatology in aged and elderly. Vaccination showed a strong association with anti-SARS-CoV-2 humoral response and an expansion of Th2 T-cells populations, independently of age. Delta variants and number of vaccine doses affected the magnitude of the humoral response against the original SARS-CoV-2 and emerging variants. A systematic surveillance of the emerging variants is paramount to define future vaccination strategies.
Keywords: COVID-19 disease severity; COVID-19 vaccine; Elderly; Immunological response; Non-vaccinated; Plasma cytokines; Pneumonia; SARS-CoV-2 variants; Th2.
. 2024 Aug 12;22(1):755.
doi: 10.1186/s12967-024-05556-2. Immune signature in vaccinated versus non-vaccinated aged people with COVID-19 pneumonia
Ruggiero Alessandra[SUP] #[/SUP][SUP] 1 [/SUP], Caldrer Sara[SUP] #[/SUP][SUP] 2 [/SUP], Pastori Claudia[SUP] 3 [/SUP], Gianesini Natasha[SUP] 1 [/SUP], Cugnata Federica[SUP] 4 [/SUP], Brombin Chiara[SUP] 4 [/SUP], Fantoni Tobia[SUP] 1 [/SUP], Tais Stefano[SUP] 2 [/SUP], Rizzi Eleonora[SUP] 2 [/SUP], Matucci Andrea[SUP] 2 [/SUP], Mayora-Neto Martin[SUP] 5 [/SUP], Uberti-Foppa Caterina[SUP] 6 [/SUP], Temperton Nigel[SUP] 5 [/SUP], Di Serio Mariaclelia Stefania[SUP] 4 [/SUP], Lopalco Lucia[SUP] #[/SUP][SUP] 7 [/SUP], Piubelli Chiara[SUP] #[/SUP][SUP] 2 [/SUP]
Affiliations
- PMID: 39135151
- PMCID: PMC11318244
- DOI: 10.1186/s12967-024-05556-2
Background: A definition of the immunological features of COVID-19 pneumonia is needed to support clinical management of aged patients. In this study, we characterized the humoral and cellular immune responses in presence or absence of SARS-CoV-2 vaccination, in aged patients admitted to the IRCCS San Raffaele Hospital (Italy) for COVID-19 pneumonia between November 2021 and March 2022.
Methods: The study was approved by local authorities. Disease severity was evaluated according to WHO guidelines. We tested: (A) anti-SARS-CoV-2 humoral response (anti-RBD-S IgG, anti-S IgM, anti-N IgG, neutralizing activity against Delta, BA1, BA4/5 variants); (B) Lymphocyte B, CD4 and CD8 T-cell phenotype; (C) plasma cytokines. The impact of vaccine administration and different variants on the immunological responses was evaluated using standard linear regression models and Tobit models for censored outcomes adjusted for age, vaccine doses and gender.
Result: We studied 47 aged patients (median age 78.41), 22 (47%) female, 33 (70%) older than 70 years (elderly). At hospital admission, 36% were unvaccinated (VAC[SUB]no[/SUB]), whilst 63% had received 2 (VAC[SUB]2[/SUB]) or 3 doses (VAC[SUB]3[/SUB]) of vaccine. During hospitalization, WHO score > 5 was higher in unvaccinated (14% in VAC[SUB]3[/SUB] vs. 43% in VAC[SUB]2[/SUB] and 44% VACno). Independently from vaccination doses and gender, elderly had overall reduced anti-SARS-CoV-2 humoral response (IgG-RBD-S, p = 0.0075). By linear regression, the anti-RBD-S (p = 0.0060), B (p = 0.0079), CD8 (p = 0.0043) and Th2 cell counts (p = 0.0131) were higher in VAC[SUB]2 + 3[/SUB] compared to VAC[SUB]no[/SUB]. Delta variant was the most representative in VAC[SUB]2[/SUB] (n = 13/18, 72%), detected in 41% of VAC[SUB]no[/SUB], whereas undetected in VAC[SUB]3,[/SUB] and anti-RBD-S production was higher in VAC[SUB]2[/SUB] vs. VAC[SUB]no[/SUB] (p = 0.0001), alongside neutralization against Delta (p = 0141), BA1 (p = 0.0255), BA4/5 (p = 0.0162). Infections with Delta also drove an increase of pro-inflammatory cytokines (IFN-α, p = 0.0463; IL-6, p = 0.0010).
Conclusions: Administration of 3 vaccination doses reduces the severe symptomatology in aged and elderly. Vaccination showed a strong association with anti-SARS-CoV-2 humoral response and an expansion of Th2 T-cells populations, independently of age. Delta variants and number of vaccine doses affected the magnitude of the humoral response against the original SARS-CoV-2 and emerging variants. A systematic surveillance of the emerging variants is paramount to define future vaccination strategies.
Keywords: COVID-19 disease severity; COVID-19 vaccine; Elderly; Immunological response; Non-vaccinated; Plasma cytokines; Pneumonia; SARS-CoV-2 variants; Th2.